Article Text
Abstract
INTRODUCTION
Stroke is a major cause of death and disability in developing and developed countries (Murray & Lopez 1996). Incidence rises steeply with age so that about three quarters of incident strokes occur in people over 65 years of age. In community-based studies among whites, around 80% of strokes are ischaemic, while 15% are due to primary intracerebral haemorrhage, and 5% to subarachnoid haemorrhage (Fig. 1). The proportion of haemorrhagic strokes in the mainly non-white populations of Asia and Africa may be somewhat higher, but ischaemic stroke is still the dominant problem (Sudlow & Warlow 1997).
The management of patients with acute ischaemic stroke aims to restore tissue perfusion, minimize cytotoxic brain damage and cerebral oedema, prevent complications of stroke, and prevent a recurrent stroke or other serious vascular event.
About 10% of patients with a first-ever acute ischaemic stroke die within 30 days of onset. Most of these early
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
- Review of current and emerging therapies in acute ischemic stroke
- Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis
- Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial
- The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
- Management of acute ischemic stroke
- Anti-inflammatory approaches to ischaemic stroke prevention
- Precision antiplatelet therapy for the prevention of ischaemic stroke
- Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke
- Cerebrovascular disease in sickle cell disease